A median PFS of 6.3 months was shown in a retrospective study involving cHL patients who progressed after PD-(L)1 inhibitors with available options including bendamustine, lenalidomide, evolimus, and gemcitabine or participation in clinical studies14. Here, CD274 is linked to classic Hodgkin lymphoma.